Trial Profile
A Randomized, Open-label Trial of Gefitinib Versus Combination of Vinorelbine Plus Platinum as Adjuvant Treatment in Pathological Stage II-IIIA(N1-N2) Non-small Cell Lung Cancer With EGFR (Epidermal Growth Factor Receptor Activating) Mutation
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 08 May 2023
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary) ; Cisplatin; Vinorelbine
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms ADJUVANT
- 01 May 2023 Results of Identification of TCR rearrangements specific for genetic alterations in EGFR-mutated non-small cell lung cancer, by deriving tumor tissues from ADJUVANT, published in the Cancer Immunology Immunotherapy
- 17 Dec 2020 Final OS results and post hoc analysis published in the Journal of Clinical Oncology.
- 21 Sep 2020 Results presented at the 45th European Society for Medical Oncology Congress